Mesobiliverdin ixα: natural anti-inflammatory compound for chronic inflammatory skin conditions

Overview

Mesobiliverdin IXα (MBV) is a naturally derived anti-inflammatory compound sourced from phycocyanobilin extracted from cyanobacteria and microalgae. It targets the complement system, a key driver of chronic inflammation, by reducing elevated levels of complement proteins C4 and C5 associated with inflammatory skin diseases. Unlike conventional treatments such as steroids and immunosuppressants, which carry significant side-effect risks, MBV offers a regenerative enzymatic mechanism that produces longer-lasting therapeutic effects. MBV-enriched microalgae (MEM) provides an additional delivery format for both research and potential therapeutic applications.

Technical specifications

• Complement modulation: MBV reduces elevated C4 and C5 levels, addressing chronic inflammation at its immunological source.
• Regenerative mechanism: MBV is reduced by biliverdin reductase, activating downstream anti-inflammatory systems in a self-sustaining cycle that distinguishes it from non-regenerative alternatives such as flavonoids.
• Dual cytoprotective and anti-inflammatory effects: Demonstrated across multiple animal models, including rats, hamsters, mice, rabbits, broilers, and piglets.
• Flexible administration: Validated via oral delivery (animal feed) and intraperitoneal injection, with effective doses ranging from 1–10 mg/kg.
• Scalable production: Natural processes developed for producing pure MBV and MEM, with industrial-scale MEM production validated at over 30 kg per batch and ongoing development for larger-scale MBV production (1–10 g per batch).
• Sustainable sourcing: Produced from toxin-free microalgae, offering an ample and environmentally friendly natural resource.

Technology readiness level

The technology has progressed through multiple validation stages. Cytoprotective effects have been confirmed in rat models for pancreatic islet allograft transplantation (2012). Anti-inflammatory efficacy was demonstrated by reducing C4 and C5 levels in a hamster viral infection model (2021). Additional validations include gut health improvements in broilers (2021), osteoporosis amelioration in mesenchymal stem cell studies (2022), and reduced antibiotic reliance in weaning piglets (2023). Industrial-scale MEM production has been achieved (2022). Ongoing efforts include scaling MBV production, developing higher-concentration MEM formulations, and seeking partners for skin disease-specific animal testing and commercialization. The technology is positioned for licensing and collaborative development toward human therapeutic applications.